Intensive BP Control Lacks Benefit in Chronic Kidney Disease

This article originally appeared here.
Share this content:
Intensive BP Control Lacks Benefit in Chronic Kidney Disease
Intensive BP Control Lacks Benefit in Chronic Kidney Disease

FRIDAY, Nov. 17, 2017 (HealthDay News) -- Intensive blood pressure (BP) control may provide no benefit and may even be harmful for patients with moderate-to-advanced chronic kidney disease, according to a study published online Oct. 16 in the Journal of Internal Medicine.

Yoshitsugu Obi, Ph.D., from the University of California Irvine Medical Center, and colleagues conducted post-hoc analysis of the Systolic Blood Pressure Intervention Trial to determine the risk-benefit profile of intensive BP control across estimated glomerular filtration rate (eGFR) levels.

The researchers found that the cardiovascular benefit from intensive treatment was diminished with lower eGFR (P interaction = 0.019), while eGFR did not alter the adverse effect on acute kidney injury (AKI; P interaction = 0.179). For the 891 participants with eGFR <45 mL/min/1.73 m2, intensive treatment did not reduce the cardiovascular outcome (hazard ratio [HR], 0.92; 95 percent confidence interval, 0.62 to 1.38), while it increased AKI (HR, 1.73; 95 percent confidence interval, 1.12 to 2.66).

"Intensive BP control may provide little or no benefit and even be harmful for patients with moderate-to-advanced chronic kidney disease," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »